lactic acid has been researched along with o-(chloroacetylcarbamoyl)fumagillol in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Kuge, Y; Misaki, M; Ogawa, Y; Okada, H; Saito, K; Toguchi, H; Yanai, S | 1 |
| Fujiie, S; Kaetsu, I; Kakinoki, S; Kato, M; Kuroda, D; Nakayama, M; Ohyanagi, H; Uchida, K; Yasuda, C; Yukutake, K | 1 |
| Di, W; Duan, Y; Liu, P; Liu, X; Qiu, L; Wang, Q; Wang, W; Wang, X; Wang, Y; Yin, X; Zhou, J | 1 |
4 other study(ies) available for lactic acid and o-(chloroacetylcarbamoyl)fumagillol
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Antitumor effect of arterial administration of a medium-chain triglyceride solution of an angiogenesis inhibitor, TNP-470, in rabbits bearing VX-2 carcinoma.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Caprylates; Carcinoma; Chemistry, Pharmaceutical; Cyclohexanes; Decanoic Acids; Doxorubicin; Female; Injections, Intra-Arterial; Lactic Acid; Male; Mitomycin; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Rabbits; Sesquiterpenes; Solutions; Triglycerides | 1995 |
Preparation of poly-lactic acid microspheres containing the angiogenesis inhibitor TNP-470 with medium-chain triglyceride and the in vitro evaluation of release profiles.
Topics: Angiogenesis Inhibitors; Chemistry, Pharmaceutical; Cyclohexanes; Delayed-Action Preparations; Drug Carriers; Drug Compounding; Drug Stability; Half-Life; Lactic Acid; Methylene Chloride; Microscopy, Electron, Scanning; Microspheres; O-(Chloroacetylcarbamoyl)fumagillol; Particle Size; Polyesters; Polymers; Sesquiterpenes; Time Factors; Triglycerides | 2003 |
Specific cell targeting with APRPG conjugated PEG-PLGA nanoparticles for treating ovarian cancer.
Topics: Angiogenesis Inhibitors; Animals; Cyclohexanes; Drug Delivery Systems; Female; Human Umbilical Vein Endothelial Cells; Humans; Lactic Acid; Mice; Nanoparticles; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Oligopeptides; Ovarian Neoplasms; Ovary; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Sesquiterpenes | 2014 |